Loading...
Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Loading earnings analysis...
Compass Score
Neutral
Key Numbers
Market Cap
$310B
P/E
18
Revenue Growth
+5.0%
Gross Margin
N/A
ROE
N/A
About AbbVie Inc.
As a mega-cap pharma company trading on the NYSE, AbbVie Inc. has established itself, with significant but diversified exposure to the biotech and genomics trend. Major pharma company with immunology and oncology pipeline post-Humira. Valued at 18x trailing earnings with a $310B market capitalization, the company demonstrates measured expansion at +5% year-over-year.
Expert Coverage
Unlock Full ABBV Analysis
Expert analysis and coverage for AbbVie Inc.
Upgrade to CompassFull access to 500+ ratings • $9/month
Price & Technical Analysis
Price50 DMA200 DMA
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
Rating last updated: 2026-05-20
More in Biotech & Genomics
LLY
Eli Lilly and Company
92
True North
Mixed
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.
NYSE
MCap $750BRev +32%P/E 65ALNY
Alnylam Pharmaceuticals
90
True North
Pure Play
RNA interference therapeutics leader with approved treatments for rare diseases.
NASDAQ
MCap $30BRev +40%CRSP
CRISPR Therapeutics
89
True North
Pure Play
Pioneer of CRISPR gene-editing therapy with first approved treatment for sickle cell disease.
NASDAQ
MCap $5BRev +350%BEAM
Beam Therapeutics
89
True North
Pure Play
Base editing platform with differentiated gene-editing pipeline.
NASDAQ
MCap $3B